Domain-alteration chimeras rewire oncogenic complexes in prostate cancer.
Transcriptional addiction to the androgen receptor (AR) underlies metastatic castration-resistant prostate cancer1, in which AR maintains oncogenic programs through domain-specific interactions with the acetyltransferases p300 and CBP (collectively p300/CBP)2. Here we describe a novel therapeutic modality, domain-alter...